Loading...
•
Dec 31, 2020
Ionis Q4 2020 Earnings Report
Ionis reported Q4 2020 earnings, achieving 2020 financial guidance and investing in wholly owned pipeline for future revenue growth.
Key Takeaways
Ionis Pharmaceuticals reported Q4 2020 financial results, achieving its 2020 financial guidance with $729 million in total revenues for the year. The company is focused on maximizing the value of its pipeline by commercializing wholly owned medicines, with key upcoming catalysts including data from multiple programs and Phase 3 tofersen data. Ionis ended the year with a strong balance sheet, holding $1.9 billion in cash.
Achieved 2020 financial guidance with $729 million in total revenues.
Advanced late-stage pipeline and expanded the utility of technology.
Expect data from multiple wholly owned programs in H1 2021 and Phase 3 tofersen data in H2 2021.
Ended 2020 with $1.9 billion in cash, enabling increasing investment in advancing the pipeline and technology.
Revenue by Segment
Forward Guidance
Ionis provided full year 2021 financial guidance, expecting revenue to be greater than $600 million, operating expenses between $675 million and $725 million, and net loss to be less than $75 million (all non-GAAP).
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...